Drugs /

genetically engineered ny-eso-1-specific t lymphocytes

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of human T-lymphocytes recognizing the tumor-associated antigen (TAA), cancer/testis antigen 1 (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Genetically engineered NY-ESO-1-specific T-lymphocytes target tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, is overexpressed on the surface of various tumor cell types.

Clinical Trials

View Clinical Trials for genetically engineered ny-eso-1-specific t lymphocytes

Genetically engineered ny-eso-1-specific t lymphocytes has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating genetically engineered ny-eso-1-specific t lymphocytes, 1 is phase 1 (1 open).

HLA-A*02:01 Positive is the most frequent biomarker inclusion criterion for genetically engineered ny-eso-1-specific t lymphocytes clinical trials.

Fallopian tube carcinoma, malignant ovarian germ cell tumor, and ovarian carcinoma are the most common diseases being investigated in genetically engineered ny-eso-1-specific t lymphocytes clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Genetically Engineered Ny-Eso-1-Specific T Lymphocytes
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating genetically engineered ny-eso-1-specific t lymphocytes and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
genetically engineered ny-eso-1-specific t cells
NCIT ID [1]:
C116846

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.